Related Experiment Video
Updated: Dec 9, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Targeted p21 activation by a new double stranded RNA suppresses human prostate cancer cells growth and metastasis
Qingsong Zhang1, Xuecheng Yang1, Lei Luo1
1Department of Urology, The Affiliated Hospital of Qingdao University Qingdao, China.
Abstract:
We have previously demonstrated that miR-1236-3p and its sequence homology dsRNA, dsRNA-245 (which is completely complementary to the p21 promoter) had potential ability to upregulate p21 expression by targeting specific promoter sequence and inhibited bladder cancer (BCa). However, we still know little about the effect of miR-1236-3p on prostate cancer and which dsRNA has an inhibitory effect on prostate cancer (PCa)? Here, we confirmed that miR-1236-3p was decreased in PCa cells and tissues. MiR-1236-3p inhibited PCa cells growth and metastasis by activating p21. Furthermore, we demonstrated that dsP21-245 could inhibit PCa cells growth and metastasis by activating p21 expression. Microarray experiments displayed that miR-1236-3p could affect AKT signaling pathway. We demonstrated that miR-1236-3p significantly suppressed the AKT pathway by inhibiting TLR2 expression while activating p21 expression in PCa cells; this influence was independent of p21 activation. In summary, our results provided evidence that both endogenous and exogenous small RNAs might function to induce p21 expression by interacting with the same promoter region, therefore impeding PCa development. Additionally, our results indicated that miRNA activation could activate the expression of some unknown genes as well as cell signaling pathways. This indicated the need for the further study of clinical applications of RNA activation.
Insights
MicroRNA-1236-3p and dsP21-245 RNA inhibit prostate cancer (PCa) by activating p21 expression. These small RNAs target the p21 promoter, suppressing tumor growth and metastasis.
Area of Science:
- Molecular Biology
- Oncology
- RNA Therapeutics
Background:
- MicroRNA-1236-3p and dsRNA-245 previously showed potential in bladder cancer by upregulating p21.
- The role of miR-1236-3p and inhibitory dsRNA in prostate cancer (PCa) remained unclear.
Purpose of the Study:
- To investigate the effect of miR-1236-3p on prostate cancer.
- To identify a dsRNA with inhibitory effects on prostate cancer.
- To elucidate the mechanism of action for miR-1236-3p and dsP21-245 in PCa.
Main Methods:
- Quantitative analysis of miR-1236-3p expression in PCa cells and tissues.
- Cell growth and metastasis assays.
- Microarray analysis to identify affected signaling pathways.
- Western blotting to assess protein expression (p21, TLR2, AKT pathway components).
Main Results:
- miR-1236-3p expression was decreased in PCa.
- Both miR-1236-3p and dsP21-245 inhibited PCa cell growth and metastasis by activating p21.
- miR-1236-3p suppressed the AKT signaling pathway by inhibiting TLR2 expression, independent of p21 activation.
- Small RNAs (endogenous and exogenous) can induce p21 expression via promoter interaction, impeding PCa development.
Conclusions:
- miR-1236-3p and dsP21-245 represent potential therapeutic agents for prostate cancer by activating p21.
- The findings highlight the role of small RNAs in regulating cancer pathways and suggest further research into RNA activation for clinical applications.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Experimental RNAi
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
DNA Damage can Stall the Cell Cycle

